
Depressive symptoms are increasingly recognized as a potentially modifiable risk factor for dementia. However, most studies have relied on total scores, thereby overlooking heterogeneity across symptom dimensions. We examined dimension-specific associations with incident dementia and the role of physical activity among 27,417 participants from the China Health and Retirement Longitudinal Study (CHARLS), the English Longitudinal Study of Ageing (ELSA), and the Health and Retirement Study (HRS). Items from the Center for Epidemiologic Studies Depression Scale (CES-D) were grouped into somatic symptoms, depressed affect, and positive affect. Incident dementia was algorithmically defined by concurrent education-stratified memory impairment and functional dependence. Cohort-specific associations were estimated using multivariable logistic regression with adjustment for baseline memory performance and pooled using random-effects meta-analysis. Higher scores for somatic symptoms and depressed affect were associated with incident dementia, with pooled odds ratios of 1.43 (95
INTRODUCTION: Few studies of cognitive impairment in COVID-19 convalescents have assessed patients longitudinally. The aim of this study was to examine the course of performance-based cognitive functions from 6 (T1) to 12 (T2) months after COVID-19 in patients compared with healthy controls, and to investigate the effect of psychiatric diagnosis and fatigue on cognitive function trajectories. METHODS: Eighty-one patients with confirmed SARS-CoV-2 infection reporting neurological symptoms were assessed at T1 and 67 patients at T2 with neuropsychological assessment and a semi-structured psychiatric interview. Fatigue was assessed using the Giessener Beschwerdebogen questionnaire (GBB). Sixty-one, confirmed SARS-CoV-2 antibody negative, healthy controls underwent neuropsychological assessment and completed GBB. RESULTS: At T1, patients performed significantly (p < 0.001 to 0.031) worse across the different cognitive domains, except for verbal fluency, than healthy controls. At T2, there were no significant differences between the two groups in either cognitive domain. Patients improved significantly from T1 to T2 on 7 of 8 domain scores (p < 0.001 to 0.033) and fatigue scores (p = 0.003). The frequency of psychiatric disorders decreased from 40% to 21%. Having a psychiatric diagnosis at T2 and/or delirium during acute COVID-19 significantly predicted a less favourable cognitive function course. CONCLUSION: These results suggest cognitive function, psychiatric morbidity and fatigue improve one year after COVID-19. Patients with ongoing psychiatric disorder and/or sequela following COVID-19-related delirium may constitute a vulnerable subgroup for non-improvement of cognitive function and should be specifically targeted for rehabilitation and treatment. TRIAL REGISTRATION: The study was registered the 09th of October 2020 at clinicaltrials.gov (NCT04576351).
Electroconvulsive therapy (ECT) is highly effective for treating severe psychiatric disorders. The molecular mechanisms underlying these disorders, and ECT’s effects remain incompletely understood. ECT may modulate growth factors and cytokines. Insulin-like growth factors (IGF)s link to neurogenesis and are altered in psychiatric disease. Data on longitudinal effects of ECT on the IGF-system across different psychiatric diagnoses, including IGF-1, IGF-binding protein 3 (IGFBP-3), IGF-2 and IGF-1/IGFBP-3 as proxy for free, active IGF-1 and its link to treatment response, is lacking. Patients undergoing ECT (n = 32) with mood disorders (n = 25) and psychotic disorders (n = 7) were investigated for IGF-1 and IGFBP-3, IGF-1/IGFBP-3 (quantified by CLIA) and IGF-2 (ELISA). Serum baseline IGF-levels were compared to levels after the sixth and last ECT and related to therapy response (global clinical improvement (CGI-I) ≤ 2 after last ECT). Associations of IGF-levels with CGI-I score were analyzed. IGF-1, IGF-1/IGFBP-3 but not IGF-2 were higher after the sixth ECT than baseline (p = 0.009; p = 0.031), adjusted for age, sex, BMI, main diagnosis and therapy response. IGF-levels did not differ between responders and non-responders. Lower global clinical improvement was linked with higher IGF-1 levels (p = 0.021), but not IGF-1/IGFBP-3 (p = 0.070), after adjusting for confounders. To our knowledge, this is the first study to longitudinally investigate the IGF-system across psychiatric diagnoses during ECT. IGF-1 and IGF-1/IGFBP-3 were elevated after the sixth ECT, independent of response. Higher symptom burden linked to higher IGF-1 and IGF-1/IGFBP-3. The observed changes may reflect neuroplastic processes, warranting mechanistic studies, but given the limited sample size, require confirmation in larger longitudinal studies.
Schizophrenia remains a major challenge in psychiatry, with diagnosis still relying largely on symptom-based assessments and lacking validated biomarkers for early detection, screening, or longitudinal monitoring. Although genomic, transcriptomic, proteomic, and metabolomic studies have revealed systemic biological dysregulation involving immune, metabolic, and neurodevelopmental pathways, conventional multiomic approaches face significant translational limitations. They often require blood or tissue sampling and can be costly; although they include both dynamic, state-sensitive and more stable, trait-like signals, their complexity and sampling burden can limit frequent or population-level use. Volatilomics, the study of volatile organic compounds (VOCs) emitted through breath, sweat, and skin, has emerged as a complementary molecular approach that may help address these gaps. VOCs represent dynamic downstream metabolic outputs and may capture rapid, state-dependent biochemical changes. Analytical and machine-learning studies have reported VOC pattern alterations in schizophrenia with promising classification accuracy in small, early-stage discovery cohorts, although independent external validation remains limited. This review examines volatilomics as a promising complementary approach with potential applications in early detection and longitudinal monitoring, and considers how integration with systemic multiomics could contribute to diagnosis, patient stratification, and precision psychiatry.